ALK and neoplasm: Tumor tissue for CLIA-certified sequencing of ALK came from diagnostic tumor or primary tumor resections in ten (25%) relapsed and five (55%) refractory patients and from biopsies at time of relapsedrefractory disease for the remainder of patients.